Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Autor: Gibbs, J. Simon R., Gomberg-Maitland, Mardi, Souza, Rogerio, Manimaran, Solaiappan, Barnes, Jennifer, Linde, Peter, de Oliveira Pena, Janethe, Badesch, David, PULSAR Trial Investigators: PULSAR Trial Investigators: Badesch, David, Humbert, Marc, McLaughlin, Vallerie, Gibbs, Simon, Gomberg-, Mardi, Maitland, Maitland, Hoeper, Marius, Preston, Ioana, de Souza, Rogerio, Waxman, Aaron, Adir, Yochai, Andrade Lima, Marina, Argula, Rahul, Baratz, David, Barberá, Joan, Bar-Shai, Amir, Berasagui, Cristina, Bertoletti, Laurent, Blanco, Daniela, Bourdin, Arnaud, Campos, Frederico, Church, Colin, Cifrian Martinez Jose, Manuel, Gerry Coghlan, John, Demarco, Teresa, Eisenmann, Stephan, Engel, Peter, Escribano Subias, Pilar, Feenstra, John, Feldman, Jeremy, Halank, Michael, Howard, Luke, Keogh, Anne, Kramer, Mordechai, LANGE, Tobias, Meyer, Gisela, Montani, David, Olsson, Karen, Ota Arakaki, Jaquelina, Pison, Christophe, Reeves, Glenn, Rischard, Franz, Safdar, Zeenat, Saggar, Rajeev, Segel, Michael, Segovia Cubero, Javier, Spikes, Leslie, Shitrit, David, Wheatley, John, t Wirtz, Huber, Brundage Bruce, Ford, Neufeld, Ellis, McGoon, Michael

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 384 (13), pp.1204-1215. ⟨10.1056/NEJMoa2024277⟩

International audience; BACKGROUND: Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e233723e2e226c41b06b76c0b2a81e7
https://hal.archives-ouvertes.fr/hal-03270003/document